In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Teva buys Biocraft Laboratories in $296 million stock swap

Executive Summary

Teva Pharmaceuticals, Israel's largest drug company, is increasing its stake in the US generics market, purchasing Biocraft Laboratories in a $296 million stock swap that values Biocraft at $20.86 a share, a 54% premium to its closing on Jan. 26.
Deal Industry
  • Pharmaceuticals
    • Generic Drugs
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition

Related Companies